Knowledge Library

Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

MSF Corporate Partner, Denis Dufresne and Corporate Associate, Molly Carroll joined client David Mehalick, Chairman of Coeptis Therapeutics Holdings Inc. this morning to ring the Nasdaq bell and open the US Markets in celebration of Coeptis’ listing on Nasdaq.

On October 31st, Coeptis Therapeutics, Inc. announced the closing of the business combination with Bullhorn Holdings Corp. When asked about the combination, David Mehalick stated, “This is a significant step for Coeptis as we seek to become a leader in the development of next generation cell therapy technologies for cancer. This transaction closely follows our recent in-licensing of SNAP-CAR, a multi-antigen CAR T technology platform, providing a springboard into what we envision will be an active period for the company.”

Please join us in congratulating our colleagues Denis Dufresne and Molly Carroll for a phenomenal job!
#business #markets #ipos #nasdaqlisted #nasdaq